Infusio Mannitoli (Mannitol)

Mannitol works by remaining in the extracellular fluid after intravenous infusion because it is not metabolized or reabsorbed by the kidneys. This creates an osmotic gradient that pulls water from intracellular spaces into the vascular compartment, increasing urine output and reducing fluid volume in the brain and eye. The resulting osmotic diuresis helps lower intracranial and intraocular pressures and facilitates renal clearance of waste products.

The dosage of Infusio Mannitoli is determined by the prescribing clinician based on the patient’s condition, weight, renal function and therapeutic goals. Typical regimens may involve an initial bolus followed by a continuous infusion, but exact rates and total daily amounts are individualized. Healthcare professionals calculate the dose according to current clinical guidelines and monitor the patient’s response and laboratory parameters.

The pregnancy category for mannitol is listed as unknown, and there are limited data on its use during lactation. Consequently, the product should be administered to pregnant or nursing women only when the anticipated therapeutic benefit outweighs any potential risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity of Infusio Mannitoli. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation. The sales team then confirms pricing, availability, shipping conditions—including any cold‑chain requirements—and assists with necessary import documentation.

The primary alternative to mannitol for reducing intracranial or intraocular pressure is hypertonic saline. While both agents create an osmotic gradient, mannitol is a non‑ionic sugar alcohol that is freely filtered and not reabsorbed, whereas hypertonic saline adds sodium chloride to the extracellular space. Mannitol generally provides a more predictable diuretic effect, but hypertonic saline may be preferred in patients with severe renal impairment where mannitol clearance is reduced.

Infusio Mannitoli should be stored at 2 °C to 8 °C in a refrigerator. The solution must be kept in its original packaging to protect it from light, and it should never be frozen or shaken vigorously, as this could affect sterility and solution integrity. Prior to use, inspect the vial for particulate matter or discoloration and discard if any abnormalities are observed.

The product is administered intravenously, either as a rapid bolus injection or as a controlled infusion, depending on the clinical indication and physician orders. Administration should be performed by qualified healthcare personnel using aseptic technique. The infusion rate is adjusted based on the target therapeutic effect and the patient’s hemodynamic and renal status, with continuous monitoring of vital signs and laboratory values.

The most critical adverse events to monitor include severe hypotension, pulmonary edema from fluid overload, electrolyte disturbances such as hyponatremia or hypokalemia, and rare anaphylactic reactions. Rapid shifts in plasma osmolality can also precipitate cardiac arrhythmias or metabolic acidosis. Prompt recognition and management of these complications, along with regular monitoring of blood pressure, electrolytes and renal function, are essential for patient safety.

Infusio Mannitoli is contraindicated in patients with known hypersensitivity to mannitol, anuria or severe renal impairment where urine output is absent, uncontrolled electrolyte imbalances, and in individuals with active pulmonary edema. Caution is also advised for patients with severe heart failure, uncontrolled hypertension, or those who are pregnant unless the therapeutic benefit justifies potential risks. Clinicians must evaluate each patient’s medical history before initiating therapy.